Manjula Kurella Tamura1, Lewis M Cohen. 1. Division of Nephrology, Stanford University School of Medicine and Geriatric Research and Education Clinical Center, Palo Alto Veterans Affairs Healthcare System, Palo Alto, California, USA. mktamura@stanford.edu
Abstract
PURPOSE OF REVIEW: In this review, we outline the rationale for expanding the role of palliative care in end-stage renal disease (ESRD), describe the components of a palliative care model, and identify potential barriers in implementation. RECENT FINDINGS: Patients receiving chronic dialysis have reduced life expectancy and high rates of chronic pain, depression, cognitive impairment, and physical disability. Delivery of prognostic information and advance care planning are desired by patients, but occur infrequently. Furthermore, although hospice care is associated with improved symptom control and lower healthcare costs at the end of life, it is underutilized by the ESRD population, even among patients who withdraw from dialysis. A palliative care model incorporating communication of prognosis, advance care planning, symptom assessment and management, and timely hospice referral may improve quality of life and quality of dying. Resources and clinical practice guidelines are available to assist practitioners with incorporating palliative care into ESRD management. SUMMARY: There is a large unmet need to alleviate the physical, psychosocial, and existential suffering of patients with ESRD. More fully integrating palliative care into ESRD management by improving end-of-life care training, eliminating structural and financial barriers to hospice use, and identifying optimal methods to deliver palliative care are necessary if we are to successfully address the needs of an aging ESRD population.
PURPOSE OF REVIEW: In this review, we outline the rationale for expanding the role of palliative care in end-stage renal disease (ESRD), describe the components of a palliative care model, and identify potential barriers in implementation. RECENT FINDINGS:Patients receiving chronic dialysis have reduced life expectancy and high rates of chronic pain, depression, cognitive impairment, and physical disability. Delivery of prognostic information and advance care planning are desired by patients, but occur infrequently. Furthermore, although hospice care is associated with improved symptom control and lower healthcare costs at the end of life, it is underutilized by the ESRD population, even among patients who withdraw from dialysis. A palliative care model incorporating communication of prognosis, advance care planning, symptom assessment and management, and timely hospice referral may improve quality of life and quality of dying. Resources and clinical practice guidelines are available to assist practitioners with incorporating palliative care into ESRD management. SUMMARY: There is a large unmet need to alleviate the physical, psychosocial, and existential suffering of patients with ESRD. More fully integrating palliative care into ESRD management by improving end-of-life care training, eliminating structural and financial barriers to hospice use, and identifying optimal methods to deliver palliative care are necessary if we are to successfully address the needs of an aging ESRD population.
Authors: Allan J Collins; Bertram Kasiske; Charles Herzog; Blanche Chavers; Robert Foley; David Gilbertson; Richard Grimm; Jiannong Liu; Thomas Louis; Willard Manning; Marshall McBean; Anne Murray; Wendy St Peter; Jay Xue; Qiao Fan; Haifeng Guo; Qi Li; Shuling Li; Yang Qiu; Suying Li; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Changchun Wang; Eric Weinhandl; Rui Zhang; Cheryl Arko; Shu-Cheng Chen; Frederick Dalleska; Frank Daniels; Stephan Dunning; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Delaney Berrini; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa Journal: Am J Kidney Dis Date: 2007-01 Impact factor: 8.860
Authors: Fliss E M Murtagh; James E Marsh; Paul Donohoe; Nasirul J Ekbal; Neil S Sheerin; Fiona E Harris Journal: Nephrol Dial Transplant Date: 2007-04-04 Impact factor: 5.992
Authors: A M Murray; D E Tupper; D S Knopman; D T Gilbertson; S L Pederson; S Li; G E Smith; A K Hochhalter; A J Collins; R L Kane Journal: Neurology Date: 2006-07-25 Impact factor: 9.910
Authors: Anne M Murray; Cheryl Arko; Shu-Cheng Chen; David T Gilbertson; Alvin H Moss Journal: Clin J Am Soc Nephrol Date: 2006-09-06 Impact factor: 8.237
Authors: Rachael L Morton; Angela C Webster; Kevin McGeechan; Kirsten Howard; Fliss E M Murtagh; Nicholas A Gray; Peter G Kerr; Michael J Germain; Paul Snelling Journal: Clin J Am Soc Nephrol Date: 2016-10-03 Impact factor: 8.237
Authors: Tim Luckett; Jane Phillips; Meera Agar; Claudia Virdun; Anna Green; Patricia M Davidson Journal: BMC Health Serv Res Date: 2014-03-26 Impact factor: 2.655
Authors: Sophia Lazenby; Adrian Edwards; Raymond Samuriwo; Stephen Riley; Mary Ann Murray; Andrew Carson-Stevens Journal: Health Expect Date: 2016-03-10 Impact factor: 3.377
Authors: Oreofe O Odejide; Ling Li; Angel M Cronin; Anays Murillo; Paul G Richardson; Kenneth C Anderson; Gregory A Abel Journal: Haematologica Date: 2018-05-10 Impact factor: 9.941